Macromolecular therapeutics: Development and delivery engineering

Gang Zhao, Xin Wei, Dong Wang

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations


Macromolecular therapeutics have been developed to improve the efficacy and safety profile of varied therapeutic agents for different disease more than 50 years ago. N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers as a drug delivery platform have been extensively studied and applied in the clinical trials. Recently, the application of HPMA copolymers in the treatment of non-cancerous diseases such like infectious diseases and musculoskeletal diseases has also been explored widely. In this chapter, different formulations of macromolecular therapeutics will be discussed. The design principles illustrated in the development of HPMA copolymer drug conjugates are also valid for other hydrophilic polymers, and they will be the principal focus of our discussion. Active targeting of HPMA copolymers based on targeting moieties and passively targeting HPMA copolymers based on the Enhanced Permeability and Retention (EPR) effect for cancer disease and Extravasation through Leaky Vasculature and subsequent Inflammatory cell-mediated Sequestration (ELVIS) mechanism for inflammation disease will also be discussed in this chapter.

Original languageEnglish (US)
Title of host publicationNeuroimmune Pharmacology
PublisherSpringer International Publishing
Number of pages15
ISBN (Electronic)9783319440224
ISBN (Print)9783319440200
StatePublished - Jan 1 2016


  • Cancer therapy
  • Central nervous system (CNS)
  • Hydroxypropyl methacrylamide HPMA copolymers
  • Targeting

ASJC Scopus subject areas

  • General Medicine
  • General Immunology and Microbiology
  • General Neuroscience
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Macromolecular therapeutics: Development and delivery engineering'. Together they form a unique fingerprint.

Cite this